

Index

A

Activin-like kinase 2 (ALK2), 67
Adams-Oliver syndrome, 52
Adenosine, 33
Adipocytes, 173
Adipogenesis, 65
Adipose-derived stem cells (ASCs), 13
A disintegrin and metalloproteinase 9 (ADAM9), 161
Akt/Jagged1/Notch signaling, 49
Alcoholic steatohepatitis (ASH), 159
Alkaline phosphatase (Alk-p), 62, 190
Allantochorionic arterial system, 133
Alpha-smooth muscle actin (α SMA), 52, 178, 190, 220
Alveolar bone regeneration, 177
Amniotic membrane-derived MSCs (AMSCs), 13
Androgen receptors (AR), 247
Angiogenesis, 74, 75, 86, 161, 171, 193, 195
 antiangiogenic treatment, 88–90
 CPEs, 91–93
 endogenous angioinhibitors, 90, 91
 PDGF, 87
 VEGF, 85, 86
Angiopoietin-1/2 (angpt-1/2), 193
Angiopoietins (Angs), 7
Angiopoietin-Tie2 axis, 75
Anti-angiogenic therapies, 19
Anticancer niche therapy, 110, 111
Anti-fibrotic strategies, 162
Anti-fibrotic therapies, 18, 19
Anti-inflammatory therapy, 15
Aorta-gonad-mesonephros (AGM), 106
Apolipoprotein E (ApoE), 156

Arteriovenous malformations (AVM), 52
Ascorbic acid, 177
Asthma, 53
Astrocytes, 4
Atherosclerosis, 198, 199
ATP-binding cassette G (ABCG2), 49
Authentic adult stem cell (ASC), 237
Autocrine signaling, 161
Autofluorescent lipid droplets, 155

B

Basic helix-loop-helix (bHLH), 170
 β -cell dedifferentiation, 28
Beta-cell dysfunction, 28, 34, 35
Beta-cell function, 28–30
 β -cell maturity, 30, 31
 insulin secretion, 32
Beta-cell mass, 36
 β -glycerophosphate, 177
Blood-brain barrier (BBB), 4
Blood retina barrier (BRB), 9, 10
Blood vessels, 170, 171, 173–175, 177–179, 181
 endothelial cells, 74, 75
 functions, 75, 76
 organs and vascular beds, 74
 vascular basement membrane, 74
Body stalk, 215
Bone marrow
 arteriolar pericytes, myeloablation, 105
 arterioles and sinusoids, mesenchymal pericytes, 105
 cellular heterogeneity, 110
 computational modeling, 107
 computational simulation, 106

- Bone marrow (*cont.*)
 developmental origins, 104
 endothelial selectins, 102
 hematologic tumors, 110
 HSC maintenance, 106–108
 HSC niches, 105, 106
 HSCs, 102, 108, 110
 leukemia development and pericytes, 109
 leukemia microenvironments, 108, 109, 111
 leukocytes, 102
 mesenchymal- and osteo-precursor cells, 103, 104
 metastatic bone cancer and pericytes, 109, 110
 microenvironments, 101
 niches, 102
 perivascular mesenchymal progenitors, 110
 vascular structure, 102
 vasculature remodeling, 6
 vessels, 103
- Bone marrow-derived cells, 174
 Bone morphogenetic protein 4 (BMP4), 35
 Bone morphogenetic proteins (BMPs), 53, 154
 Bovine placental vascularization, 134
 Brain-derived neurotrophic factor (BDNF), 195
 Bromodeoxyuridine (BrdU), 241
- C**
 Caldesmon, 190
 Calponin, 190
 Cancer stem cells, 110
 Capillary blood flow regulation, 74
 Capillary system, 127, 130, 133, 137
 Cardiac fibrosis, 200
 Cardiac homeostasis, 194
 angiogenesis, 193, 195
 vascular integrity and perfusion, 193
 vascular tone, 195, 196
 Cardiac pericytes (cPC)
 anatomical location, 190
 biology, 203, 204
 characterization, 190, 191
 markers, 192
 origin, 189
 subtypes, 204
 swine model, 204
 type-1 pericytes, 204
 vascular integrity, stability and remodeling, 203
 Cardiovascular pathophysiology, 189
 atherosclerosis, 198, 199
 calcification, 199
 cardiac fibrosis, 200
 myocardial ischemic disease, 196–198
 thrombosis, 200, 201
 Cat placental vascularization, 135
 Cell outgrowth, 176
 Cellular architecture, 190
 Central nervous system (CNS), 4, 116
 Chemokine receptor 3 (CXCR3), 195
 Chondrogenesis, 66, 67
 Chronic liver diseases
 death and liver transplantation, 73, 81
 endothelial cells, 74
 GVB (*see* Gut-vascular barrier (GVB))
 pathological angiogenesis (*see* Angiogenesis)
 portal hypertensive syndrome, 81–83
 portosystemic collaterals, 84, 85
 postnatal vasculogenesis, 93, 94
 splanchnic blood flow, 82, 83
 Chronic pulmonary diseases, 50
 Clonogenicity, 173
 Cochlear blood flow, 118–120
 Cochlear blood flow regulation, 119
 Cochlear capillary pericytes
 blood supply, 117
 CNS, 116
 morphology and cellular markers, 118
 pathologies, 116
 pathophysiology, 119, 120
 pharmacotherapy, 121
 physiological functions, 118, 119
 precapillary arteriolar cells, 116
 smooth muscle actin and tropomyosin, 116
 stria vascularis/spiral ligament, 116, 117, 121
 subpopulations, 116
 Colony-forming unit-fibroblastic (CFU-f), 172
 Connexin-43 (Cx43), 191
 Cre-loxP technology, 46, 48
 C-type natriuretic peptide (CNP), 195
 CXCL12, 175
 CXCL12-abundant reticular (CAR), 106
 Cytokine niches, 108
 Cytoplasmic polyadenylation element binding proteins (CPEB), 85
 Cytoplasmic polyadenylation elements (CPEs), 91–93
- D**
 Dental pulp stem cells (DPSCs), 178
 Desmin, 190
 Dexamethasone, 177

Diabetic macular edema (DME), 15
 Diabetic retinopathy (DR)
 angiogenic growth factors, 13
 BRB, 14, 15
 cell-based therapy, 15–17
 glutamate excitation, 14
 neovascularization, 14
 ophthalmologic examinations, 14
 treatments, 15
 vascular permeability and
 microaneurysms, 13
 visual impairment and blindness, 13
 Diphtheria toxin (DT), 48
 Diphtheria toxin receptor (DTR), 48
 Duchenne muscular dystrophy (DMD), 61

E

Ectomesenchyme, 251
 Embryogenesis, 43
 Embryonal development, 3
 Endogenous angioinhibitors, 90, 91
 Endometrial stromal cells, 141
 Endothelial cells, 74, 75
 Endothelial nitric oxide synthase (eNOS), 86
 Endothelial progenitor cells (EPCs), 15
 Endothelin-1 (ET-1), 157
 Endotheliochorial lamellar placenta, 133
 Endotoxin, 120
 Enzymatic digestion methods, 176
 E-selectin, 102
 Ethane dimethanesulfonate (EDS), 237
 Eutherian mammals, 126
 Exotoxin, 120
 Extracellular matrix (ECM), 160, 194
 Extravillous trophoblast (EVT), 132, 139

F

Farnesoid X receptor (FXR), 160
 Fetal development, 212, 214, 218, 220
 Fibro/adipogenic progenitors (FAPs), 65
 Fibroblast-associated genes, 226
 Fibroblast growth factor receptor 1
 (FGFR1), 157
 Fibroblast growth factors (FGFs), 154
 Fibroblastic colony-forming units (CFU-F), 103
 Fibroblasts, 172
 Fibrodysplasia ossificans progressiva
 (FOP), 66
 Fibrosis, 65, 66, 154
 5-fluorouracil (5FU), 105
 Follistatin, 156

G

Galectin-3, 200
 Ganglion cell layer (GCL), 5
 Ganglioside 3g5 (3g5), 190
 Gastroesophageal varices, 84
 Gastrointestinal tract, 77
 Gene therapy, 89
 Gestation, 212, 214, 217, 220
 Gestational diabetes mellitus (GDM), 228
 Gestation umbilical cord, 225
 Glioma-associated oncogene 1 (Gli1), 190
 Gliotoxin, 156
 Glucocorticoid therapy, 199
 Glucose homeostasis
 β -cell maturity (*see* Beta-cell function)
 β -cell replication, 32, 33
 blood flow, 33
 endothelial, neuronal and immune
 cells, 30
 Glucose-stimulated insulin secretion, 28,
 30–32, 34, 35
 Gonadal stem cell (GSC), 244
 G protein-coupled receptors (GPCRs), 159
 Gut-liver axis, 95, 96
 Gut-vascular barrier (GVB), 97
 disruption, 97
 endothelial cells, 96
 gut-liver axis, 95, 96
 lamina propria, 95
 morphological and functional
 characteristics, 96
 murine and human intestines, 96
 peripheral tissues, 96
 PV1, 96

H**Heart**

cardiovascular diseases, 189
 cell-based therapeutics, 202, 203
 cPC (*see* Cardiac pericytes (cPC))
 disease progression, 189
 endothelial barrier function, 188
 homeostasis (*see* Cardiac homeostasis)
 microvascular, arteriole/venular, 203
 MSCs, 201, 202
 pathophysiology (*see* Cardiovascular
 pathophysiology)
 pericytes, 188
 repair and regeneration, 201
 tissue physiology and disease, 189
 Heat shock cognate (HSC) 70, 173
 Heat shock protein (HSP) 70, 173

- Hematopoietic stem cells (HSCs), 101, 102, 105–108, 110, 111, 172
- Hemochorial labyrinthine placenta, 132, 133
- Hemochorial villous placenta, 130, 132
- Hemotrophic placentation, 126
- Heparin-binding epidermal growth factor (HB-EGF), 75, 194
- Hepatic stellate cells (HSCs)
description, 153
developmental origin, 154
healthy liver, 155, 156
hepatic metastases, 160–161
steatohepatitis, 159–160
- Hepatocellular carcinoma, 157, 160
- Hepatocyte growth factor (HGF), 156, 198
- Hepatocytes, 156–160
- Hereditary hemorrhagic telangiectasia (HHT), 52, 53
- Histiotrophic placentation, 126
- House dust mite (HDM), 53
- Human aortic ring (hAR) assay, 225
- Human cytomegalovirus (HCMV), 138
- Human myelodysplastic syndrome cells, 109
- Human placental vascularization, 131
- Human spiral arteriole, 140
- Human umbilical cord perivascular cells (HUCPVCs), 220
- Hyperglycemia, 35, 36
- Hypoxia, 171, 175
- Hypoxia inducible factor-1 α (HIF1 α), 171
- I**
- Immune response, 119, 120
- Immunoreactivity, 246
- Indoleamine 2,3-dioxygenase (IDO), 139
- Induced pluripotent stem (iPS) cells, 181
- Inferior mesenteric arteries (IMA), 81
- Inflammatory cytokine, 197
- Injured hepatocytes, 157
- Inner nuclear layer (INL), 3
- Interferon beta (IFN β), 159
- Interleukin 10 (IL-10), 156
- Intestines
functional considerations, 79, 80
gastrointestinal tract, 76
macroscopic anatomical considerations, 76–78
microscopic anatomical considerations, 78, 79
- Intra-islet density, 33
- Intramuscular adipose tissue (IMAT), 65
- Intrastrial blood-fluid barrier, 118
- Islet capillaries, 29, 33, 36
- Islet pericytes, 29, 31, 33
- Islets of Langerhans, 28, 33
- Islet vasculature, 28, 29, 33
- Ito cells, 153
- K**
- Kidney fibrosis models, 18
- Kupffer cells, 157, 158, 160
- L**
- Laser photocoagulation, 15
- Lecithin retinol acyltransferase (LRAT), 155
- Leptin receptor (Lepr), 106
- Leukemia cells, 108, 109
- Leukemia development, 109
- Leukemic stem cell (LSC), 110
- Leydig cells, 236, 237, 241, 246, 253, 255
and sertoli cells, 247
- Lipocytes, 153
- Lipopolysaccharide (LPS), 158
- Liver
HSCs (*see* Hepatic stellate cells (HSCs))
- Liver fibrosis, 156, 157
autophagy, 159
cell types, 157
chronic injury, 157
ET-1, 157
HSC activation, 157, 159
HSC migration, 157
HSCs, 158
injured hepatocytes, 158
MCP-1, 157
retinoic acid signaling, 158
SECs, 157
substrate stiffness, 159
- Liver regeneration, 156
- Liver sinusoidal endothelial cells (LSECs), 153
- Lung pericytes
anatomic characterization, 42, 43
animal models
Cre recombinase activity, 48
Cre recombinase expression, 46
DT, 48
embryogenesis, 47
FoxD1-derived cells, 46
FoxJ1-CreER transgene, 48
lineage tracing, 47
LoxP sequences, 46
NG2, 48
oropharyngeal aspiration, 48
pulse labeling, 47

- ROSA locus, 46
 - tamoxifen, 48
 - asthma, 53
 - cell morphology and characteristics, 44
 - developmental origins, 43
 - gene markers, 45
 - HHT, 52, 53
 - homeostasis and repair, 49–50
 - inflammation and injury, 50, 51
 - inflammatory response, 51
 - microvascular endothelium, 42
 - microvascular permeability and stability, 53
 - molecular identification and pericyte
 - subtypes, 43, 44, 46
 - myofibroblast precursors, 45
 - PAH, 52
 - pathogenesis, 53
 - pulmonary fibrosis, 42, 51, 52
 - pulmonary hypertension, 42
 - skin and gut epithelium, 49
 - transgenic mice, 47
 - vascular homeostasis, 42
- M**
- Mastication, 170
 - Maternal-fetal communication, 127
 - Matrix metalloproteinase 2 (MMP2), 161
 - Matrix metalloproteinases (MMPs), 194
 - Melanoma cell adhesion molecule (MCAM), 46
 - Mesenchymal progenitor cells (MPCs), 49
 - Mesenchymal stem cells (MSCs), 13, 50, 102, 103, 172, 173, 176–179, 181, 182, 201, 202, 219, 245
 - Mesenchymoangioblast (MB), 62
 - Mesenteric arteries, 78
 - Mesenteric microcirculation, 81
 - Mesenteric vascular bed, 82
 - Mesentery, 80–81
 - Mesoangioblasts, 60, 64, 65
 - Metablast, 251
 - Microangiopathy, 49
 - Microvascular dysfunction, 50
 - Microvascular physiology, 74
 - Microvessels, 76
 - Monocyte chemoattractant protein-1 (MCP-1), 156
 - Morphological method, 75
 - Mouse adipose-derived stem cells (mASCs), 16
 - Multipotent stromal cells (MSCs), 244
 - Mural cells, 190
 - Muscle injury, 61, 63, 64, 66
 - Muscle regeneration, 60, 61, 63–65, 67
 - Muscular dystrophy
 - muscle injury, 61
 - myogenic and non-myogenic activities, 67
 - pericytes, 61
 - SCs, 60
 - skeletal muscle (*see* Skeletal muscle injury)
 - Myelodysplastic syndrome, 109
 - Myeloproliferative disorder model, 109
 - Myoblasts, 59
 - Myocardial infarction (MI), 196, 198, 201–204
 - Myocardial ischemic disease, 196
 - Myofiber hypotrophy, 61
 - Myofibroblasts, 49, 51, 53, 222
 - Myogenesis, 63–65, 67
 - Myogenic differentiation, 60, 64, 67
- N**
- Nanog (NANOG), 191
 - N-cadherin, 11, 195
 - Nerve growth factor (NGF), 32
 - Nerve injury, 67
 - Nestin immunoreactivity, 249
 - Neural crest cells (NCCs), 154, 251
 - Neural stem cells (NSCs), 104, 251
 - Neural fold (NF), 251
 - Neural glial antigen-2 (NG2), 4, 44, 62, 178, 190
 - Neurosensory retina, 3
 - Neurovascular unit (NVU), 9
 - NG2 proteoglycan, 8
 - Niches, 102, 104, 105, 110
 - Nitric oxide (NO), 157
 - Nonalcoholic steatohepatitis (NASH), 159, 160, 162
 - No-reflow, 196
 - Notch-3, 198
- O**
- Obstetrical complications, 212, 227–229
 - Octamer-binding transcription factor 4 (OCT4), 191
 - Optic nerve (ON), 2
 - Osler-Weber-Rendu syndrome, 52
 - Osteoblasts, 173
 - Osteogenesis/ossification, 66, 67
 - Outer nuclear layer (ONL), 2, 3
 - Outgrowth endothelial cells (OECs), 15–16
 - Oxygen-induced retinopathy (OIR), 11

P**Pancreas**

- α- and β- cells, 28
- blood glucose levels, 28
- diabetes, 28
- exocrine and endocrine cells, 28

Pancreatic pericytes

- cytoplasmic processes, 29
- embryonic pancreatic mesenchyme, 29
- endothelial cells, 29
- exocrine pancreas, 29
- glucose homeostasis (*see* Glucose homeostasis)

Paracrine, 161**PDGF-receptor β (PDGFRβ), 4, 43, 46, 47, 49, 62, 137, 190****Pericytes**

- HSCs (*see* Hepatic stellate cells (HSCs))
- periodontal tissue (*see* Periodontal ligament)

Periodontal ligament

- anatomy, function and distinctiveness, 170–171
- bone marrow cells, 175
- GFP-positive cells, 174
- HUVECs, 180
- MSCs, 176–177
- pericytes
 - blood vessels, 178
 - cell kinetic analysis and cytology, 178
 - GFP transgenic mice, 178–179
 - H³-thymidine, 178
 - lineage tracing method, 179
 - markers, 178
 - microvasculature, 177
 - morphometry, 178
 - MSCs, 178, 181
 - multipotency, 178
 - neural crest, 179
 - PDLSCs, 179
 - precaution, 179
 - stem cells, 178
 - 10T1/2 cells, 179
 - treatments, 181
 - vascular endothelium, 179
- stem cells (*see* Periodontal ligament stem cells (PDLSCs))
- tissue regeneration, 171–172

Periodontal ligament stem cells (PDLSCs), 172–176**Periostin, 170, 171****Peritubular myoid cell (PMC), 247****Perivascular cells, 102, 106, 139, 188, 203, 242–243****Peroxisome proliferator-activated receptor (PPAR), 160****Peroxisome proliferator-activated receptor gamma (PPARγ), 159****Pigment epithelium-derived factor (PEDF), 90****Placenta**

- blood flow, 128, 129
- eutherian diversification, 126
- hemotrophic and histiotrophic bipotential, 126
- pericytes
 - angiogenesis signaling, 136, 137
 - applications, 136
 - cell differentiation, 141
 - functions, 135
 - immune system, 135
 - knockout/null-induced placental abnormalities, 137, 138
 - placental immune cells regulation, 139, 140
 - regenerative tissue and repair processes, 135–136
 - vascular stability, 135

variability

- allantois, 126
- arterial and venous levels, 128
- carnivores, 128
- classification, 126
- cotyledonary, 127
- extraembryonic membranes, 126
- invasive deepness, 128
- maternal-fetal communication units, 127
- models, 127
- morphological differences, 126
- noninvasive epitheliochorial placenta, 128
- rodents and lagomorphs, 128
- tissue layers, 127
- trophoblast layers, 128

vascular architecture

- capillary systems/microvasculature, 130
- endotheliochorial lamellar placenta, 133
- hemochorial labyrinthine placenta, 132, 133
- hemochorial villous placenta, 130, 132
- synepitheliochorial villous placenta, 133

Placental growth factor (PGF), 136**Placental vascularization, 126****Plasmalemma vesicle-associated protein-1 (PV1), 96****Platelet-derived growth factor (PDGF), 87****Platelet-derived growth factor B (PDGF-B), 7, 136****Platelet-derived growth factor bb (PDGFbb), 191**

- Pluripotent microvascular pericytes
 adipocytes, 245
 astrocytes, 252
 COUP-TFII, 248, 250
 EDS, 246, 248
 embryonic ectoderm, 253
 epiblast, 254
 genetic changes, 245
 history, 242
 human testis, 239
 hypothesis, 253
 hypoxia, 248
in vivo experiment, 236
 Leydig cells, 236
 mesenchymal stem cells, 254
 NCSCs, 251, 253
 PDGFR- α and PDGFR- β , 247
 PMCs, 248
 seminiferous tubules, 239
 sertoli cells, 246
 sources, 243
 steroid hormones, 239
 testis, 236
 transdifferentiation, 250
 vascularized organ, 240
 vertebrate organism, 244
- Pneumolysin, 120
- Portal hypertensive syndrome, 81, 82
- Portosystemic collateral vessels, 82, 84, 85
- Preeclampsia (PE), 229
- Proliferation cell nuclear antigen (PCNA), 105
- Pro-nerve growth factor (pro-NGF), 197
- Protease-activated receptor-2 (PAR2), 159
- P-selectin, 102
- Pulmonary arterial hypertension (PAH), 52
- Pulmonary endothelial dysfunction, 52
- Pulmonary fibrosis, 42, 51, 52
- Pulmonary hypertension, 42
- Q**
- Quail chick transplantations, 5
- R**
- Rat testis interstitium, 249
- Reactive oxygen species (ROS), 157
- Regenerative medicine, 212, 225, 228
- Regenerative therapy, 176, 177
- Regulator of G protein signaling 5 (RGS5),
 62, 191
- Retina
 BRB, 9, 10
 DR (*see* Diabetic retinopathy (DR))
 human eye, 2
 identification, 4, 5
 image processing, 3
 NG2 proteoglycan, 8
 ON, 2
 origin, 5–7
 pathological retinal neovascularization, 10
 PDGFRb/PDGFB, 7, 8
 photoreceptors, 3
 ROP (*see* Retinopathy of prematurity
 (ROP))
 synapses, 2
 Tbx18, 9
 tissue regeneration and wound healing,
 17–19
 vascular beds, 3, 4
- Retinal angiogenesis, 49
- Retinal ganglion cell (RGC), 14
- Retinal pigment epithelial (RPE) cells, 3
- Retinal vascular development, 3, 4
- Retinols, 155
- Retinopathy of prematurity (ROP)
 blood vessels, 10
 CCN1 expression, 11
 cell based therapies, 12, 13
 EC-PC communication, 11
 fibrous scar tissue, 11
 hyperoxia, 12
 hypoxia, 10
 IGF-1, 11
 laser photocoagulation and anti-VEGF
 therapies, 11
 mural cells, 12
 neovascularization, 12
 neovascular vessels/tufts, 10
 OIR, 11
 oxygen-sensitive growth factors, 10–11
 rodents, 11
 vascular development, 10
- Root region, 80
- Rouget-Mayer cells, 243
- S**
- Saethre-Chotzen syndrome, 170
- Satellite cells (SCs), 59–61, 63
- Scanning electron microscopy (SEM), 178
- Scarring, 65
- Schwann cells, 67
- Septum transversum, 154
- Sertoli cells, 239, 247
- Serum protein, 119
- Sex-determining region box (SOX2), 191
- Sharpey's fibers, 172

- Single nucleotide polymorphism (SNP), 34
 Sinusoidal endothelial cells (SECs), 157, 158
 Sirtuin 3 (SIRT3), 198
 Skeletal muscle
 limb ischemia model, 61
 muscular dystrophy
 adipogenesis, 65
 chondrogenesis and osteogenesis/
 ossification, 66, 67
 fibrosis, 65, 66
 myogenesis, 63–65
 myofibers, 59
 nerve injury, 67
 pericyte physiology
 cellular markers, 62
 origins, 62
 structure and density, 61
 pericytes, 60, 64
 pericyte subtypes, 63
 satellite cells, 60
 SCs, 60
 Smooth muscle actin (SMA), 173
 Smooth muscle α -actin (α -SMA), 62
 Smooth muscle cells (SMCs), 52
 Sonic hedgehog (Shh), 159
 Sorafenib, 89
 Spermatogenesis, 239
 Sphingosine-1-phosphate (S1P), 195
 Splanchnic neovasculature, 88
 Steatohepatitis, 157
 alcoholic and nonalcoholic liver disease, 160
 cholesterol, 160
 etiologies, 159
 inflammation and fibrogenesis, 159
 liver diseases, 159
 neutrophils, 160
 pro-inflammatory cytokines, 160
 TLRs, 160
 Stem cell factor (SCF), 106
Streptococcus pneumoniae, 119
Streptococcus pyogenes, 119
 Streptolysin, 120
 STRO-1^{bright}/HSP70⁻ cell population, 173
 Stromal-derived factor 1 (SDF-1), 157, 175, 179
 Sudden sensorineural hearing loss (SSNHL), 119
 Superior mesenteric arteries (SMA), 81
 Suppurative labyrinthitis, 120
 Synepitheliochorial villous placenta, 133
- T**
 T-box protein 18 (Tbx18), 9, 190
 Tbx18-lineage cells, 50
 T-cadherin, 198
 T-cell factor/lymphoid enhancer factor (TCF/
 LEF), 34
 Testes and epididymides, 238
 Testicular interstitium, 238
 Testicular pericytes, 237
 Thrombosis, 200, 201
 Tissue dependency, 17
 Tissue factor (TF), 190
 Tissue inhibitor of metalloproteinase-1
 (TIMP-1), 156
 Tissue metabolism, 177
 Tissue regeneration, 17–19
 Toll-like receptors (TLRs), 160
 Transdifferentiation, 245, 249, 250
 Transforming growth factor beta (TGF β), 7,
 53, 156, 194
 Transit amplifying cells, 244–246, 248–250,
 254
 Transmission electron microscopy, 42, 217
 Trophoblast giant cells (TGC), 132
 Tropomyosin receptor kinase B (TrkB), 195
 Tumor growth factor (TGF)- β 1, 136
 Tumor progression, 161
 Twist, 170
 Type 2 diabetes
 β -cell, 28
 glycemic control, 31
 insulin resistance, 28
 pancreatic pericytes
 β -cell dysfunction, 34, 35
 hyperglycemia, 35, 36
- U**
 Umbilical artery, 225
 Umbilical cord
 allantois and yolk sac, 214
 application, 218
 blood vessels, 214
 CD146+ cells, 223
 CD146 expression, 220, 222
 cell phenotypes, 219, 223
 contractile cells, 218
 cord lengthens, 214
 embryonic processes, 212
 endothelial and perivascular cells, 217
 erythrocyte-filled vessels, 218
 gestation, 217
 groundbreaking research study, 219
 growth curve, 218
 HUCPVCs, 221, 225
 intra-abdominal part, 217
 jellylike substance, 212
 mammals, 217

mesenchymal progenitor cells, 219
 mesenchymal stromal cells, 212
 mesenchyme tissue connection, 214
 microvessels, 217
 MSCs, 219, 224
 pathology, 227
 pericyte-associated markers, 212
 pericyte-like cells, 218
 perivascular cells, 219
 sign, 214
 stromal cells, 223
 structural and functional regions, 214
 structural organization, 218
 UCWJ, 226
 vascularization, 212
 veins, 217
 vSMC, 222
 WJ, 222, 227, 228
 Umbilical cord Wharton's jelly (UCWJ), 225
 Uterine natural killers (uNK), 132

V

Vascular basement membrane, 32
 Vascular calcification, 199
 Vascular calcification-associated factor
 (VCAF), 199
 Vascular cell adhesion molecule-1
 (VCAM-1), 102
 Vascular endothelial growth factor
 (VEGF), 7, 75, 85, 86, 136, 159
 Vascular endothelial growth factor A
 (VEGF-A), 194

Vascular endothelium, 179
 Vascular integrity, 189, 193
 Vascular network, 170, 171, 179
 Vascular niche, 236, 245, 254, 255
 Vascular progenitor cells, 202
 Vascular smooth muscle cells
 (vSMCs), 4–5, 29
 Vascular stem cells, 94, 189, 202
 Vascular tone, 189, 195, 196
 Vasculature, 212, 214, 218, 219, 225
 Vasoconstriction, 75
 Vasodilation, 75
 Vasohibin-1, 91
 VEGF receptor (VEGFR), 159
 VEGF receptor 2 (VEGFR2), 194
 Villi vasculature, 79
 Vimentin, 190
 Vitamin A, 155, 156
 Vitamin D3 receptor (VDR), 160
 von Willebrand factor (vWF), 191

W

Wharton's jelly (WJ), 222, 226, 227
 Wild-type (WT), 156
 Wilm's tumor 1 (WT1), 154
 Wnt/ β -catenin pathway, 49, 199
 Wnt-1-Cre mouse model, 5
 Wound healing, 17–19

Z

Zygote and blastocyst differentiation, 252